Education
About Us
Working with TipRanks
Follow Us
Collplant Holdings (CLGN)
NASDAQ:CLGN
Top Page
Collplant Holdings
(NASDAQ:CLGN)
Rating:44Neutral
Price Target:
$2.50
▼(-4.58% Downside)
Positive Factors
Innovative Technology
Collplant's proprietary collagen technology, derived from genetically modified plants, positions it well in the regenerative medicine field, offering a competitive edge in developing advanced tissue repair solutions.
Strategic Partnerships
Strategic partnerships with healthcare firms and research institutions enhance Collplant's revenue potential and provide funding, supporting long-term growth and innovation in regenerative medicine.
Low Debt Levels
A low debt-to-equity ratio reflects a conservative leverage approach, which provides financial flexibility and reduces risk, supporting long-term stability.
Negative Factors
Revenue Decline
A drastic decline in revenue indicates challenges in sustaining market demand or operational issues, which could impact long-term growth and profitability.
Negative Cash Flow
Significant negative cash flow suggests operational inefficiencies and financial strain, potentially limiting the company's ability to invest in growth and innovation.
Weak Financial Stability
Decreasing equity and asset base indicate weakening financial stability, which may hinder the company's ability to weather economic challenges and invest in future opportunities.
Collplant Holdings (CLGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$33.32M
Dividend YieldN/A
Average Volume (3M)34.73K
Price to Earnings (P/E)―
Beta (1Y)0.66
Revenue Growth248.62%
EPS Growth26.22%
CountryUS
Employees57
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.28
Shares Outstanding12,716,014
10 Day Avg. Volume10,264
30 Day Avg. Volume34,726
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.22
Enterprise Value/Revenue14.41
Enterprise Value/Gross Profit-5.34
Enterprise Value/Ebitda-0.46
Forecast
1Y Price Target
$11.00Price Target Upside319.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Collplant Holdings Business Overview & Revenue Model
Company DescriptionCollplant Holdings (CLGN) is a biotechnology company specializing in regenerative medicine and tissue repair. The company focuses on developing innovative solutions based on its proprietary collagen technology, which is derived from genetically modified tobacco plants. Collplant's core products include a range of collagen-based therapies and medical devices aimed at enhancing wound healing, tissue regeneration, and reconstructive surgery. The company operates primarily in the healthcare sector, targeting applications in orthopedics, aesthetic medicine, and other areas requiring tissue reconstruction and repair.
How the Company Makes MoneyCollplant generates revenue through the commercialization of its collagen-based products and therapies. Its primary revenue streams include sales of medical devices and therapeutic products designed for wound care and tissue regeneration. Additionally, the company may engage in strategic partnerships with other healthcare firms, research institutions, and pharmaceutical companies to co-develop products or license its technology, further enhancing its revenue potential. Collaborations and partnerships may also provide funding through grants or milestone payments, contributing to its overall earnings. The company's focus on developing novel applications of its collagen technology positions it to capitalize on growing market demands in the regenerative medicine field.
Collplant Holdings Earnings Call Summary
Earnings Call Date:Aug 20, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Nov 26, 2025
Earnings Call Sentiment Neutral
Despite significant advancements in preclinical programs and continued collaboration with AbbVie, the company experienced a sharp decline in annual revenue and increased net losses, presenting a mixed financial outlook.Q4-2024 Updates
Positive Updates
Photocurable Dermal Filler Preclinical Success
The photocurable dermal filler candidate is in the preclinical phase, targeting a market valued at approximately $6.3 billion with a compound annual growth rate of 10%. Positive feedback from leaders in aesthetic medicine suggests it could be a game-changer for facial plastic surgery.
Regenerative Breast Implant Program Progress
Preclinical testing of commercial-sized breast implants (250cc) shows promising outcomes with depolarization and rapid tissue ingrowth, no complications, and maintained volume retention. This product could revolutionize breast reconstruction and aesthetic enhancements.
AbbVie Collaboration and Financial Milestone
CollPlant received a $2 million payment from AbbVie following development achievements in their dermal filler clinical trials, indicative of continued collaboration and potential future milestones.
Cash Runway Stability
Cash and cash equivalents as of December 31, 2024, were $11.9 million, with an expected operational runway through the second quarter of 2026.
Negative Updates
Significant Revenue Decline
Revenue for the year ended December 31, 2024, was $515,000, a sharp decrease from $11 million in 2023, mainly due to a $10 million milestone payment in 2023 not repeated in 2024.
Increased Net Loss
GAAP net loss for the year ended December 31, 2024, was $16.6 million compared to a net loss of $7 million for the year 2023, highlighting increased financial strain.
Company Guidance
During the CollPlant Biotechnologies Ltd. investor call, CEO Yehiel Tal and Deputy CEO Eran Rotem provided guidance centered on their regenerative medicine advancements, notably highlighting their proprietary photocurable dermal filler and regenerative breast implant programs. The dermal filler, aimed at a market valued at approximately $6.3 billion with a 10% CAGR, is currently in the preclinical phase, with plans to launch a clinical trial within two years. The regenerative breast implant program is progressing with preclinical testing of 250cc commercial-sized prototypes, showing promising results in tissue integration without complications. Financially, CollPlant reported a decrease in revenue from $11 million in 2023 to $515,000 in 2024, primarily due to a $10 million milestone payment from AbbVie in 2023. Despite a GAAP net loss of $16.6 million in 2024 compared to $7 million in 2023, the company maintains a stable cash position of $11.9 million as of December 31, 2024, not accounting for an additional $2 million payment from AbbVie, ensuring operational capability into the second quarter of 2026.Collplant Holdings Financial Statement Overview
Summary
Collplant Holdings is facing significant financial challenges, with a drastic revenue decline, negative profit margins, and deteriorating cash flow. Despite low debt levels, the company's shrinking asset base and equity indicate financial instability.Income Statement
Collplant Holdings has experienced significant revenue volatility, with a notable revenue decline from $10.96 million in 2023 to $0.515 million in 2024. The company is struggling with negative margins, including a gross profit margin of -215% and a net profit margin of -3226% in 2024. Despite a brief profitable period in 2021, consistent negative EBIT and EBITDA margins indicate ongoing operational challenges.35
Negative
Balance Sheet
The company's debt-to-equity ratio remains low at 0.23 in 2024, reflecting a conservative leverage approach. However, stockholders' equity has decreased significantly, and the equity ratio has dropped from 88% in 2021 to 72% in 2024, indicating weakening financial stability. The company's asset base has also shrunk considerably over the same period.50
Neutral
Cash Flow
Collplant Holdings' free cash flow has deteriorated significantly, with a negative free cash flow of $14.58 million in 2024, compared to $3.72 million in 2023. The operating cash flow to net income ratio and free cash flow to net income ratio are both negative, showing a lack of cash flow generation. Despite previous years of positive cash flow from financing activities, the company's cash reserves are depleting.30
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 515.00K | 10.96M | 299.00K | 15.64M | 6.14M |
| Gross Profit | -1.11M | 8.97M | -101.00K | 13.64M | 3.13M |
| EBITDA | -16.21M | -6.41M | -16.02M | 838.00K | -4.94M |
| Net Income | -16.61M | -7.02M | -16.75M | 409.00K | -5.81M |
Balance Sheet | |||||
| Total Assets | 18.71M | 34.13M | 37.77M | 51.22M | 10.84M |
| Cash, Cash Equivalents and Short-Term Investments | 11.91M | 26.67M | 29.65M | 43.30M | 3.33M |
| Total Debt | 3.08M | 3.16M | 2.91M | 3.61M | 3.39M |
| Total Liabilities | 5.25M | 5.79M | 5.49M | 6.10M | 6.36M |
| Stockholders Equity | 13.46M | 28.34M | 32.28M | 45.12M | 4.48M |
Cash Flow | |||||
| Free Cash Flow | -14.58M | -3.72M | -15.01M | 912.00K | -4.97M |
| Operating Cash Flow | -14.09M | -2.76M | -13.70M | 2.50M | -4.45M |
| Investing Cash Flow | -539.00K | -1.16M | 28.92M | -31.56M | -519.00K |
| Financing Cash Flow | 9.00K | 1.11M | 1.87M | 38.76M | 4.46M |
Collplant Holdings Technical Analysis
Neutral
2.62
Price Trends
2.35
Positive
2.14
Positive
2.81
Negative
Market Momentum
0.07
Positive
51.56
Neutral
55.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLGN, the sentiment is Neutral. The current price of 2.62 is above the 20-day moving average (MA) of 2.61, above the 50-day MA of 2.35, and below the 200-day MA of 2.81, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 51.56 is Neutral, neither overbought nor oversold. The STOCH value of 55.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLGN.
Collplant Holdings Risk Analysis
Collplant Holdings disclosed 81 risk factors in its most recent earnings report. Collplant Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Collplant Holdings Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.92B | -0.36 | -43.38% | 2.25% | 22.38% | -2.17% | |
47 Neutral | $62.74M | ― | -87.74% | ― | -60.16% | ― | |
44 Neutral | $33.32M | ― | -78.25% | ― | 248.62% | 26.22% | |
41 Neutral | $35.36M | ― | -312.77% | ― | ― | 61.18% | |
40 Underperform | $11.33M | ― | -67.47% | ― | ― | 9.63% | |
39 Underperform | $56.76M | ― | -104.21% | ― | ― | 39.60% | |
35 Underperform | $6.98M | ― | -133.62% | ― | -86.43% | -8.91% |
* Healthcare Sector Average
Performance Comparison
CLGN
Collplant Holdings
2.62
-2.38
-47.60%
PYPD
PolyPid
3.47
-0.09
-2.53%
ALXO
ALX Oncology Holdings
1.06
-1.12
-51.38%
SPRB
Spruce Biosciences
12.40
-21.81
-63.75%
ALGS
Aligos Therapeutics
10.20
-4.02
-28.27%
SNSE
Sensei Biotherapeutics
8.98
-0.60
-6.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.